Alanna Schepartz
Overview
Explore the profile of Alanna Schepartz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
228
Citations
2527
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karp H, Zoltek M, Wasko K, Vazquez A, Brim J, Ngo W, et al.
Nucleic Acids Res
. 2025 Mar;
53(5).
PMID: 40036508
Effective genome editing requires a sufficient dose of CRISPR-Cas9 ribonucleoproteins (RNPs) to enter the target cell while minimizing immune responses, off-target editing, and cytotoxicity. Clinical use of Cas9 RNPs currently...
2.
Schissel C, Roberts-Mataric H, Garcia I, Kang H, Mowzoon-Mogharrabi R, Francis M, et al.
J Am Chem Soc
. 2025 Feb;
147(8):6503-6513.
PMID: 39933167
Despite tremendous efforts to engineer translational machinery, replacing the encoded peptide backbone with new-to-nature structures remains a significant challenge. C, H, O, and N are the elements of life, yet...
3.
Fricke R, Knudson I, Swenson C, Smaga S, Schepartz A
Nat Protoc
. 2025 Jan;
PMID: 39762443
Aminoacyl-tRNA synthetases (aaRSs) provide an essential functional link between an mRNA sequence and the protein it encodes. aaRS enzymes catalyze a two-step chemical reaction that acylates specific tRNAs with a...
4.
Karp H, Zoltek M, Wasko K, Vazquez A, Brim J, Ngo W, et al.
bioRxiv
. 2024 Oct;
PMID: 39464099
Effective genome editing requires a sufficient dose of CRISPR-Cas9 ribonucleoproteins (RNPs) to enter the target cell while minimizing immune responses, off-target editing and cytotoxicity. Clinical use of Cas9 RNPs currently...
5.
Vazquez Maldonado A, Chen T, Rodriguez D, Zoltek M, Schepartz A
bioRxiv
. 2024 Oct;
PMID: 39386431
Abstract Figure:
6.
Soni C, Prywes N, Hall M, Nair M, Savage D, Schepartz A, et al.
ACS Cent Sci
. 2024 Jul;
10(6):1211-1220.
PMID: 38947215
Using directed evolution, aminoacyl-tRNA synthetases (aaRSs) have been engineered to incorporate numerous noncanonical amino acids (ncAAs). Until now, the selection of such novel aaRS mutants has relied on the expression...
7.
Cruz-Navarrete F, Griffin W, Chan Y, Martin M, Alejo J, Brady R, et al.
ACS Cent Sci
. 2024 Jul;
10(6):1262-1275.
PMID: 38947208
Templated synthesis of proteins containing non-natural amino acids (nnAAs) promises to expand the chemical space available to biological therapeutics and materials, but existing technologies are still limiting. Addressing these limitations...
8.
Hamlish N, Abramyan A, Shah B, Zhang Z, Schepartz A
ACS Cent Sci
. 2024 May;
10(5):1044-1053.
PMID: 38799653
The programmed synthesis of sequence-defined biomaterials whose monomer backbones diverge from those of canonical α-amino acids represents the next frontier in protein and biomaterial evolution. Such next-generation molecules provide otherwise...
9.
Zoltek M, Vazquez Maldonado A, Zhang X, Dadina N, Lesiak L, Schepartz A
ACS Cent Sci
. 2024 Apr;
10(4):860-870.
PMID: 38680556
The inefficient translocation of proteins across biological membranes limits their application as potential therapeutics and research tools. In many cases, the translocation of a protein involves two discrete steps: uptake...
10.
Giudice J, Brauer D, Zoltek M, Vazquez Maldonado A, Kelly M, Schepartz A
bioRxiv
. 2024 Apr;
PMID: 38617268
ZF5.3 is a compact, rationally designed mini-protein that escapes efficiently from the endosomes of multiple cell types. Despite its small size (27 amino acids), ZF5.3 can be isolated intact from...